V503 + Placebo to V503
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancers
Conditions
Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
Trial Timeline
Feb 24, 2010 → Nov 28, 2015
NCT ID
NCT01047345About V503 + Placebo to V503
V503 + Placebo to V503 is a phase 3 stage product being developed by Merck for Cervical Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT01047345. Target conditions include Cervical Cancers, Vulvar Cancers, Vaginal Cancers.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancers were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01047345 | Phase 3 | Completed |
Competing Products
20 competing products in Cervical Cancers